Product Description
Baminercept, an LTbetaR-Ig fusion protein, and pacteclizumab, an anti-LTalpha antibody, have been investigated as treatments for rheumatoid arthritis (RA), but they failed in both instances to produce significant clinical efficacy (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115299/)
Mechanisms of Action: FP Inhibitor
Novel Mechanism: No
Modality: Fusion Protein
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biogen
Company Location: CAMBRIDGE MA 02142
Company CEO: Michel Vounatsos
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Arthritis, Rheumatoid|Sjogren's Syndrome|Multiple Sclerosis, Chronic Progressive|Colitis, Ulcerative
Phase 1: Hepatitis C, Chronic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ASJ02 | P2 |
Terminated |
Sjogren's Syndrome |
2015-01-01 |
|
| 2010-019558-42 | P2 |
Completed |
Colitis, Ulcerative |
2012-10-23 |
|
| 2007-000734-38 | P2 |
Completed |
Arthritis, Rheumatoid |
2010-02-17 |
|
| 2007-000733-19 | P2 |
Terminated |
Arthritis, Rheumatoid |
2008-10-09 |